FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
